Provider Survey: Prior Auths in HI

Photo by Christin Hume on Unsplash

In December 2022, MedQUEST sent out an updated memo on hepatitis C treatment that specifically stated:

• “The goal of this HCV policy is to assure adherence to the best practice guidance, currently outlined by the AASLD-IDSA HCV Guidance. For treatment regimens following the AASLD- IDSA HCV Guidance, there will be no prior authorization [emphasis added]”

We are partnering with the Hawaiʻi Department of Health to determine if this guidance is being implemented in a timely and consistent manner throughout Hawaiʻi.

Please complete this survey on prior authorizations that you were required to complete for hep C treatment in 2023. You can provide info on an individual prior authorization or more general feedback. Aggregate data may be used or shared to guide program and policy action, but individual level data will not be shared without consent. The survey will remain open until July 15, 2023.